What Happens If an IM Injection Missed the Muscle?

When an intramuscular injection ends up in the layer of fat beneath the skin instead of the muscle, the medication still enters your body, but it absorbs more slowly and less predictably than intended. In most cases, this means a delayed or weakened drug effect and a higher chance of a local reaction like pain, swelling, or a persistent lump. For some medications, though, the consequences are more serious, and the mismatch between where the drug was supposed to go and where it actually landed can genuinely matter for your health.

Why Muscle and Fat Handle Drugs Differently

Muscle tissue has a rich blood supply, which is the whole reason certain drugs are designed to be injected there. Blood flowing through muscle picks up the medication quickly and carries it into your general circulation, where it can start working. Fat tissue underneath the skin is less vascular, so a drug deposited there absorbs more slowly and at a less predictable rate.¹ The practical result is that peak drug levels in your blood tend to be lower, and it takes longer to reach them.

This is not always a disaster. Some medications are specifically designed to be injected subcutaneously (into the fat layer), and they work just fine there. Insulin is a good example. But when a drug is formulated for muscle delivery, accidentally depositing it in fat changes its behavior in ways the prescriber did not plan for. The drug may pool in the tissue rather than dispersing evenly, the onset may lag, and the total amount that eventually reaches your bloodstream can be unpredictable.

What This Means for Vaccines

Vaccines are the most common intramuscular injection most people receive, and they are also the category where a missed muscle is most likely to cause a visible local reaction without necessarily being dangerous. Many vaccines contain aluminum-based adjuvants, compounds added to boost your immune response. When those adjuvants end up in subcutaneous fat instead of muscle, they are much more likely to trigger local inflammation, the formation of granulomas (small lumps of immune tissue), and in some cases, persistent nodules that can last months.²

These granulomas form because the fat tissue absorbs the aluminum slowly, giving your immune system prolonged exposure to the irritant. In muscle, the same adjuvant disperses and clears faster. Case reports describe subcutaneous aluminum granulomas appearing as firm lumps, sometimes visible on imaging, occasionally accompanied by persistent itching.³ One case in a one-year-old showed subcutaneous lesions measuring up to 16 mm after vaccination, confirmed by biopsy to contain aluminum deposits. In another reported case, a patient developed persistent subcutaneous nodules and sterile abscesses linked to delayed-type hypersensitivity to aluminum, confirmed by patch testing.⁴

Beyond the local reactions, there is an efficacy concern. Lower seroconversion rates and reduced antibody persistence have been reported when certain vaccines land subcutaneously rather than intramuscularly.² In plain terms, your body may not mount as strong or as lasting an immune response. Whether this makes a meaningful clinical difference depends on the specific vaccine, but it is the reason guidelines emphasize proper technique.

Granulomas and Fat Necrosis at the Injection Site

Injection granulomas are believed to form more readily in subcutaneous fat than in muscle because fat has a comparatively disorganized vascular network. The injected material hangs around longer, giving your body more time to wall it off with immune cells.⁵ In rare cases, a granuloma can grow large enough or look unusual enough on imaging to mimic a soft tissue tumor, which leads to unnecessary biopsies and anxiety before it is correctly identified.

Fat necrosis is another local complication. When a drug intended for muscle is injected into fat, the medication itself can damage the fatty tissue. This shows up as firm, encapsulated, mobile nodules under the skin, often painless, that may persist for weeks or months. A case report described fat necrosis caused by intramuscular injections of cefazolin (an antibiotic) that were deposited too superficially.⁶ These lumps are generally harmless but can be alarming and slow to resolve.

When the Medication Cannot Afford to Be Slow

For most vaccines and routine medications, a subcutaneous deposit is a nuisance. For epinephrine during anaphylaxis, it can be a life-threatening problem. Epinephrine needs to reach the bloodstream fast, and muscle delivery achieves that. When an epinephrine autoinjector fails to penetrate deep enough and deposits the drug in fat instead, peak blood levels are lower and take longer to arrive.⁷

Research on epinephrine injections confirms that intramuscular delivery produces faster absorption in the first several minutes after injection, which is exactly when speed matters most during a severe allergic reaction.⁸ In a study of overweight and obese women using an autoinjector with a shorter needle, ultrasound showed that 10 out of 12 women received the epinephrine subcutaneously rather than intramuscularly. The time to peak concentration tripled compared to a proper intramuscular injection with a longer needle, jumping from about 5 minutes to 15 minutes.⁹ That delay, researchers noted, may help explain why obese individuals with rapidly progressing anaphylaxis face worse outcomes even when they use an autoinjector promptly.

Long-acting injectable antipsychotics used to treat schizophrenia are another category where proper muscle delivery matters. These formulations are engineered to release medication gradually from a depot in the muscle over weeks. If the injection ends up in fat instead, the drug may not maintain the steady blood levels needed to prevent breakthrough psychotic episodes.¹⁰ For a person relying on a monthly injection to stay stable, that difference is not trivial.

Who Is Most Likely to Have a Missed-Muscle Injection

Body composition is the single biggest factor. Women tend to carry thicker subcutaneous fat at common injection sites than men. In one large ultrasound study, women had substantially thicker subcutaneous tissue at the thigh and abdomen compared to men.¹¹ This means the standard one-inch needle used for most deltoid injections has to travel farther through fat before it reaches muscle in many women, and it may not get there at all.

Higher BMI makes the problem worse. Research evaluating standard needle lengths found that a one-inch needle may fail to reach the deltoid muscle in a substantial proportion of adults with obesity.¹² At the buttock (dorsogluteal site), the picture is even more stark. One study estimated that 1.5-inch needles would fail to reach muscle in about 71% of women with a BMI over 30 and about 60% of men with a BMI over 35 when injecting at the ventral gluteal site.¹³ A systematic review of dorsogluteal injections concluded that women with a BMI of 25 or higher may need needles longer than 1.5 inches to clear the subcutaneous layer, while men generally need longer needles only at a BMI of 35 and above.¹⁴

Gender, BMI, and body shape all independently predict how thick the fat layer is at a given injection site. Females, individuals with obesity, and those with a rounder body shape consistently have thicker subcutaneous fat and are more likely to receive a subcutaneous injection when a standard intramuscular technique is used.¹⁵ This is a genuine health equity issue: the standard needle lengths embedded in many clinical guidelines were calibrated for average-sized adults, and a growing proportion of the population does not fit that assumption.

Choosing the Right Injection Site

Not all injection sites are equally forgiving. The deltoid (upper arm) is the most common site for vaccines and many medications, but it has relatively thin muscle in some individuals, especially those who are smaller or older. The dorsogluteal site (upper outer buttock) was traditionally the go-to for gluteal injections, but it carries the thickest layer of subcutaneous fat of the common sites and the greatest risk of missing the muscle.

The ventrogluteal site (the side of the hip) has been promoted as a safer alternative. Ultrasound measurements in older adults found that the ventrogluteal site had thicker muscle and thinner subcutaneous tissue compared to the dorsogluteal site.¹⁶ Cross-sectional studies confirm that subcutaneous fat tends to be thicker at the dorsogluteal site, while muscle and total tissue thickness at the ventrogluteal site provides a more reliable target.¹⁷

That said, a meta-analysis comparing the two sites found no statistically significant difference in the rate of inadvertent subcutaneous injections.¹⁸ The ventrogluteal site does offer other advantages, though. It is farther from the sciatic nerve and major blood vessels, reducing the risk of nerve damage and accidental intravascular injection. The evidence collectively favors the ventrogluteal site for gluteal injections, even if its superiority for actually reaching muscle is less dramatic than some nursing guidelines imply.

Nerve Damage and Other Serious Complications From Misplaced Injections

While landing in fat instead of muscle is the most common miss, injections that go awry in other directions can cause far worse outcomes. Sciatic nerve injury from a gluteal injection is the most frequent and serious neurological complication of intramuscular injections.¹⁹ The sciatic nerve runs through the buttock, and a needle placed too medially or too inferiorly can strike it directly or deposit irritating medication next to it. The consequences range from temporary numbness to intractable neuropathic pain. One case report described a 68-year-old man left with persistent nerve pain after a gluteal injection of an analgesic hit his sciatic nerve.²⁰

Accidental intravascular injection is another hazard. If the needle enters a blood vessel instead of muscle, the medication can be delivered directly into the bloodstream all at once. For certain drugs like benzathine penicillin, this can cause a range of injuries, from damage to the distal extremities to central nervous system complications including seizures and, in extreme cases, death.²¹ These events are rare, but they highlight why proper injection technique involves more than just choosing the right needle length.

Infection Risk When Injections Miss Their Target

Subcutaneous tissue is more vulnerable to infection than muscle, in part because it has less blood flow. That reduced circulation means fewer immune cells patrol the area and any contamination that gets introduced has a better foothold. A review of necrotizing fasciitis cases following intramuscular injections identified 19 cases in the literature over a 20-year span, with a notable concentration in immunosuppressed patients and people with chronic diseases.²² The same review noted that injecting into the subcutaneous layer carries a higher infection risk than proper intramuscular placement precisely because the tissue is less vascularized.

Necrotizing fasciitis from injections is rare but devastating when it occurs. Cases have been reported after gluteal injections in which the medication caused local tissue damage that became a gateway for aggressive bacterial or even fungal infection.²³ The risk climbs when unsterile technique is involved, such as shared needles or contaminated medications, but it can also occur after properly administered injections in individuals whose immune systems are compromised.

Techniques That Reduce the Chances of Missing

Several practical strategies help ensure the medication reaches muscle. The most straightforward is matching needle length to the patient’s body size. This sounds obvious, but many clinical protocols still default to a one-inch needle for deltoid injections and a 1.5-inch needle for gluteal injections regardless of the patient’s build. The evidence suggests these defaults fail a large segment of the population, particularly women and people with higher BMI. Some researchers have called for guideline revisions that incorporate BMI-specific needle-length recommendations.¹²

The Z-track technique is another tool. Instead of inserting the needle straight in, the administrator displaces the skin and subcutaneous tissue laterally before injecting, then releases it after withdrawing the needle. This creates a zigzag track that prevents the medication from leaking back through the injection channel. A study of intramuscular diclofenac injections found that the Z-track technique significantly reduced drug leakage at the injection site compared to the standard technique.²⁴ While this technique does not directly ensure that the needle reaches muscle, reducing leakage means more of the medication stays where it was deposited.

Site selection, as discussed earlier, also plays a role. Using the ventrogluteal site instead of the dorsogluteal site for hip injections moves the needle away from the sciatic nerve and into an area where muscle is typically closer to the surface. For the deltoid, pinching the skin to lift subcutaneous tissue away or bunching the muscle to bring it closer to the needle tip are techniques some clinicians use, though their effectiveness varies by patient build.

What to Do If You Suspect an Injection Missed

If you receive an intramuscular injection and develop a hard lump at the site that persists for more than a few days, or notice unusual pain, redness, or swelling that worsens rather than improves, it is worth mentioning to your healthcare provider. A persistent, painless nodule after a vaccine may simply be a granuloma or a pocket of fat necrosis, and these generally resolve on their own over weeks to months without treatment. Warm compresses and gentle massage of the area can sometimes help.

For medications where efficacy depends on proper delivery, particularly epinephrine autoinjectors, knowing your body composition matters. If you carry more weight around your thighs and have been prescribed an autoinjector, ask your allergist or prescriber whether the standard needle length is adequate for you. Some autoinjector brands have longer needles than others, and this is not a detail most patients think to ask about until the research on failed IM delivery in larger patients makes the issue clear.⁹

Signs that something more serious has gone wrong include sudden sharp shooting pain down the leg during a gluteal injection (which could indicate nerve contact), rapid swelling and warmth at the injection site over the following days (which could signal infection), or systemic symptoms like fever. These warrant prompt medical attention. Fortunately, the vast majority of intramuscular injections, even those that technically miss the muscle, cause nothing more than temporary soreness and perhaps a slower-than-ideal response from the medication.

The Insulin Analogy, and Why Route Matters Both Ways

An interesting flip side to this whole topic is that some drugs are designed to go into subcutaneous fat on purpose, and accidentally hitting muscle with those drugs creates problems in the opposite direction. Insulin is the classic example. Injected subcutaneously, insulin absorbs at a controlled, predictable pace. If it accidentally goes into muscle, the richer blood supply causes it to absorb much faster, which can lead to larger swings in blood sugar and an increased risk of dangerously low glucose levels.¹ This is why insulin injection technique emphasizes pinching a fold of skin and injecting at a shallow angle, specifically to avoid going too deep.

The broader lesson is that route of delivery is not an afterthought in drug design. Medications are formulated with a specific tissue target in mind, and the absorption characteristics of that tissue are baked into the dosing instructions. When the drug ends up in the wrong compartment, whether too deep or too shallow, the carefully calibrated balance between dose and absorption shifts, sometimes meaningfully. For most people and most injections, the margin of error is wide enough that a slight miss is inconsequential. But for time-sensitive drugs, depot formulations, and adjuvanted vaccines, the tissue the needle reaches genuinely matters.